HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Spillmann, R. Articles by de Sanchez, C. E. Search for Related Content PubMed PubMed Citation Articles by Spillmann, R. Articles by de Sanchez, C. E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB METRONIDAZOLE

Double-Blind Test of Metronidazole and Tinidazole in the Treatment of Asymptomatic Entamoeba histolytica and Entamoeba hartmanni Carriers^*

One hundred and fifteen persons with asymptomatic Entamoeba histolytica or E. hartmanni infection, or both, were given metronidazole (750 mg three times daily for 5 days), tinidazole (1 g twice daily on 2 consecutive days), or a starch placebo. Three posttreatment stools were examined in the 2 weeks following initiation of treatment. Cysts of E. histolytica reappeared in the stools of 37% of 30 given metronidazole, 62% of 34 given tinidazole, and 70% of 31 given placebo. Cysts of E. hartmanni reappeared in the stools of 46% of 24 given metronidazole, 69% of 16 given tinidazole, and 90% of 10 given placebo. Rapid absorption and short duration of treatment make both drugs ineffective for the treatment of ameba carriers.

Accepted for publication December 6, 1975.

^* This research was supported in part by the Universidad del Valle Facultad de Medicina, and by the Tulane University Center for Medical Research Grant AI-100050 from the National Institutes of Health, U. S. Public Health Service.

Address reprint requests to: International Center for Medical Research, Tulane Medical Center, 1430 Tulane Avenue, New Orleans, Louisiana 70112.